Takeda Digital Ventures

Takeda Ventures, Inc. (TVI), founded in 2001, is the corporate venture capital arm of Takeda Pharmaceutical Company Limited. TVI focuses on early-stage, preclinical opportunities that align with Takeda's R&D pillars: Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal & Inflammation. Their portfolio includes notable companies such as Amwell, Avidity Biosciences, and Xilio Therapeutics. TVI's investment strategy emphasizes high-caliber, therapeutic, platform-based companies worldwide, primarily in North America, Europe, and Japan. The average investment ranges from seed to Series B rounds, with TVI often co-investing alongside major venture firms like OrbiMed and Johnson & Johnson Innovation. TVI's approach includes taking board seats and providing strategic guidance, leveraging Takeda's extensive global resources and expertise to drive value-based outcomes for patients. The team is based in Cambridge, MA, and includes seasoned professionals like Miles Gerson (Head & President) and Jasmina Marjanovic, Ph.D. (Partner). They prioritize a hands-on, collaborative approach, working closely with portfolio companies to foster innovation and therapeutic advancements. TVI actively seeks to build relationships with academic innovators, entrepreneurs, and venture investors to cultivate a robust pipeline of breakthrough therapies. For startups looking to connect, TVI values companies with early commercial traction and those that embody a patient-first approach, reflecting Takeda’s core values.